Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Safety of deep sedation in young children with sickle cell disease: a retrospective cohort study
source: The Journal of Pediatrics
year: 2015
authors: Belmont AP, Nossair F, Brambilla D, Friedman M, Boswinkel J, Bradford AB, Kwiatkowski JL
summary/abstract:OBJECTIVE:
To assess the rates and types of complications associated with deep sedation in children with sickle cell disease (SCD) and to explore potential risk factors.
STUDY DESIGN:
This was a retrospective cohort study of children with SCD and a comparison group of children without SCD who underwent magnetic resonance imaging with deep sedation. The rates of general and SCD-associated sedation complications were calculated, and potential associated clinical and laboratory variables were assessed.
RESULTS:
A total of 162 sedation records in 94 subjects with SCD and 324 sedation records in 321 subjects without SCD were assessed (mean age, 4.3 years in both groups). Pentobarbital, fentanyl, and midazolam were used in the majority of sedation episodes without routine presedation transfusion. Sedation-related complication rates did not differ significantly between the SCD and comparison groups. Within 1 month after the sedation procedure, 17 children (10%) experienced a vaso-occlusive pain episode (VOE), and 2 children (1.2%) developed acute chest syndrome. Preprocedure and postprocedure rates of these complications did not differ significantly. Subjects who developed VOE after sedation had a significantly higher VOE rate before sedation, but no other significant clinical or laboratory risk factors were identified.
CONCLUSION:
Deep sedation in young children with SCD using a standard protocol is safe, with a sedation-related complication rate comparable to that of the general pediatric population. The observed rate of VOE, although not significantly higher than expected, warrants further investigation.
DOI: 10.1016/j.jpeds.2015.01.054
read more full text
+myBinderRelated Content
-
Cognitive function, coping, and depressive symptoms in children and adolescents with sickle cell diseaseOBJECTIVE: The objective of this study ...
-
Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemiaChildren with sickle cell anemia (SCA) s...
-
Dr. Doris Wethers, 91, on Front Lines against Sickle Cell, DiesDr. Doris L. Wethers, who broke racial b...
-
Sickle cell gene linked to elevated risk of developing kidney failureNew research indicates that being born w...
-
Providing Expert Care for Pregnant Sickle Cell Patienthttps://www.youtube.com/watch?v=rTebitxq...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory ComplicationsThe U.S. Food and Drug Administration (F...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.